Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong

References

• Meltzer HY. What's atypical about atypical antipsychotic drug?. Curr Opin Pharmacol. 2004; 4: 53–7.
   PubMed Web of Science ®Google Scholar
• Simpson GM. A brief history of depot neuroleptics. J Clin Psychiatry. 1984; 53: 3–4.
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of people with schizophrenia. Am J Psychiatry. 1997; 154(Suppl).
   Google Scholar
• Gardner DM, Baldessarini RJ, Waraich P. Modern anti-psychotic drug: a critical overview. Can Med Assoc J. 2005; 172: 1703–11.
   PubMed Web of Science ®Google Scholar
• Manchanda R, Norman RMG. Schizophrenia: early intervention. Can J Contin Med Educ. 2003; 11: 123–7.
   Google Scholar
• Moller HJ. Antipsychotic agents: gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry. 2005; 20: 379–85.
   PubMed Web of Science ®Google Scholar
• Anath J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004; 10: 2219–29.
   Google Scholar
• Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: Part II: adverse effects, drug interactions, and costs. Ann Pharmacother. 1999; 33: 210–7.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Scott Stroup T, McEovy JP, Swartz MS, Rosenheck RA, Perkins DO, . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005; 353: 1209–23.
   PubMed Web of Science ®Google Scholar
• Bartko G, Varadi H, Simon L, Linka E, Tuske T, Szabo T, . Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiatr Clin Pract. 2002; 6: 9–14.
   PubMed Web of Science ®Google Scholar
• Cook PE, Goldberg J, van Lieshout RJ. Benefits of switching from typical to atypical antipsychotic medications: A longitudinal study in a community based setting. Can J Psychiatry. 2002; 47: 870–4.
   PubMed Web of Science ®Google Scholar
• Hellewell JS. Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs. 2002; 16: 457–71.
   PubMed Web of Science ®Google Scholar
• Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry. 2006; 39: 47–51.
   Web of Science ®Google Scholar
• Lesile DL, Rosenheck RA. Second annual report on schizophrenia pharmacotherapy in VA. West Haven, CT: Department of Veterans Affairs, Northeast Program Evaluation Center; 2001.
   Google Scholar
• Sarfati Y, Olivier V, Bouhassira M. New antipsychotics in the treatment of schizophrenia: A European survey. Encephale. 1999; 25: 658–66.
   PubMed Web of Science ®Google Scholar
• Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, . Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci. 2004; 58: 61–7.
   PubMed Web of Science ®Google Scholar
• Hamann J, Adjan S, Leucht S, Kissling W. Psychiatric decision making in the adoption of a new antipsychotic in Germany. Psychiatr Serv. 2006; 57: 700–3.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry. 1997; 58: 63–72.
   PubMedGoogle Scholar
• Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. J Clin Psychiatry. 1999; 60: 23–29.
   PubMedGoogle Scholar
• Hofer A, Kemmler G, Eder U. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry. 2002; 63: 49–53.
   PubMed Web of Science ®Google Scholar
• Tsang HWH, Fung, KMT, Corrigan PW. Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia. J Behav Ther Exp Psychiatry. 2009; 40: 3–14.
   PubMed Web of Science ®Google Scholar
• Yamada K, Watanabe K, Nemoto N, Fujita H, Chikaraishi C, Yamauchi K, . Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res. 2006; 141: 61–9.
   Google Scholar
• Helbling J, Ajdacic-Gross V, Lauber C, Weyermann R, Burns T, Rossler W. Attitudes to antipsychotic drugs and their side effects: a comparison between general practitioners and the general population. BMC Psychiatry. 2006; 6: 42–.
   PubMedGoogle Scholar
• Huffman JC, Blais MA, Pril WF. A comparison of clinician and patient concerns about antipsychotic side effect: a pilot study. J Nerv Ment Dis. 2004; 192: 328–30.
   Google Scholar
• Bond GR, Kim HW, Meyer PS, Gibson PJ, Tunis S, Evans JD, . Response to vocational rehabilitation during treatment with first- or second-generation antipsychotics. Psychiatr Serv. 2004; 15: 245–55.
   Google Scholar
• Malla AK, Norman RMG, Scholten DJ, Zirul S, Kotteda V. A comparison of long term outcome in first episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry. 2001; 62: 179–84.
   PubMed Web of Science ®Google Scholar
• Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand. 1996; 96: 381–8.
   Google Scholar
• . Equal Opportunities Commission. Full Report: A baseline survey on employment situation of persons with a disability in Hong Kong; 1997.
   Google Scholar
• Tsang HWH, Chen EYH. Perceptions on remission and recovery in schizophrenia. Psychopathology. 2007; 40: 469–.
   PubMedGoogle Scholar
• Lehman AF. Measures of quality of life among persons with severe and persistent mental disorders. Soc Psychiatry Psychiatr Epidemiol. 1996; 31: 78–88.
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LNP, Heslegrave RJ. Preliminary validation of conceptual model to assess quality of life in schizophrenia. Qual Life Res. 1997; 6: 21–6.
   PubMed Web of Science ®Google Scholar
• Tsang HWH, Angell B, Corrigan PW, Lee YL, Shi K, Lam CS, . A cross-cultural study of employers’ concerns about hiring people with psychotic disorder: Implications for recovery. Soc Psychiatry Psychiatr Epidemiol. 2007; 42: 723–33.
   PubMed Web of Science ®Google Scholar
• Lloyd HM, Markwick AJ, Page ER, Lewis S, Barnes TRE. Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the cutlass study. Int J Psychiatry Clin Pract. 2005; 9: 35–40.
   PubMed Web of Science ®Google Scholar
• Parker G, Lambert T, McGrath J, McGorry P, Tiller J. Neuroleptic management of schizophrenia: a survey and commentary on Australian psychiatric practice. Aust NZ J Psychiatry. 1998; 32: 50–8.
   PubMed Web of Science ®Google Scholar
• Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry. 2008; 42: 369–81.
   PubMed Web of Science ®Google Scholar